Microba Life Sciences Limited (MAP.AX)
AUD 0.19
(0.0%)
AUD 0.19
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -26.84 Million AUD | -32.71% |
| 2023 | -20.22 Million AUD | -76.61% |
| 2022 | -11.45 Million AUD | -19.67% |
| 2021 | -9.57 Million AUD | -29.22% |
| 2020 | -7.4 Million AUD | -54.65% |
| 2019 | -4.78 Million AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -15.3 Million AUD | -113.99% |
| 2024 FY | -26.79 Million AUD | -32.45% |
| 2024 Q1 | -7.15 Million AUD | 36.48% |
| 2024 Q4 | -11.49 Million AUD | 0.0% |
| 2023 Q1 | -4.48 Million AUD | 48.03% |
| 2023 Q4 | -11.25 Million AUD | -100.0% |
| 2023 FY | -20.22 Million AUD | -76.61% |
| 2023 Q3 | -5.62 Million AUD | 37.26% |
| 2023 Q2 | -8.97 Million AUD | -99.93% |
| 2022 Q1 | -3.81 Million AUD | 29.65% |
| 2022 Q4 | -8.63 Million AUD | -99.79% |
| 2022 FY | -11.45 Million AUD | -19.67% |
| 2022 Q3 | -4.32 Million AUD | 43.43% |
| 2022 Q2 | -7.63 Million AUD | -100.24% |
| 2021 Q3 | -2.68 Million AUD | 35.21% |
| 2021 FY | -9.57 Million AUD | -29.22% |
| 2021 Q4 | -5.42 Million AUD | -101.83% |
| 2021 Q2 | -4.14 Million AUD | -100.0% |
| 2021 Q1 | -2.07 Million AUD | 0.0% |
| 2020 FY | -7.4 Million AUD | -54.65% |
| 2019 FY | -4.78 Million AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Australian Clinical Labs Limited | 56.9 Million AUD | 147.171% |
| BCAL Diagnostics Limited | -5.44 Million AUD | -392.785% |
| Genetic Signatures Limited | -22.33 Million AUD | -20.194% |
| Genetic Technologies Limited | -6.53 Million AUD | -310.62% |
| Healius Limited | 39.7 Million AUD | 167.614% |
| Imagion Biosystems Limited | -15.81 Million AUD | -69.738% |
| Integral Diagnostics Limited | 5.36 Million AUD | 600.147% |
| INOVIQ Ltd | -9.51 Million AUD | -182.244% |
| Monash IVF Group Limited | -5.34 Million AUD | -402.3% |
| Rhythm Biosciences Limited | -6.7 Million AUD | -300.208% |
| Sonic Healthcare Limited | 816.45 Million AUD | 103.288% |